|
Mar 29
|
Labcorp inks $237.5M buyout of Opko’s reproductive, women’s health testing assets
|
|
Mar 28
|
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
|
|
Mar 25
|
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
|
|
Mar 20
|
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
|
|
Mar 5
|
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
|
|
Jan 11
|
Shockwave Medical (SWAV) Surges 7.8%: Is This an Indication of Further Gains?
|
|
Jan 9
|
OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes
|
|
Dec 7
|
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
|
|
Dec 6
|
Why Is OPKO Health (OPK) Up 18.7% Since Last Earnings Report?
|
|
Nov 15
|
Phillip Frost Spends US$1.3m On OPKO Health Stock
|
|
Nov 7
|
Q3 2023 OPKO Health Inc Earnings Call
|
|
Nov 7
|
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
|
|
Nov 7
|
OPKO Health, Inc. (NASDAQ:OPK) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
|
|
Nov 7
|
Opko Health (OPK) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
OPKO Health (OPK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Nov 6
|
OPKO Health Inc (OPK) Reports Third Quarter 2023 Financial Results
|
|
Nov 6
|
OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results
|
|
Nov 2
|
New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023
|
|
Oct 25
|
OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023
|